NCT03616886: Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

NCT03616886
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated, unstable, symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT03616886

Comments are closed.

Up ↑